Who is sponsoring NCT06170008?

NCT06170008 is sponsored by Changhai Hospital.

What condition does NCT06170008 study?

NCT06170008 studies Second-degree Burn Wounds, Skin Graft Wounds.

Is NCT06170008 still recruiting?

NCT06170008 is currently not yet recruiting. Last updated 14 December 2023.

Last reviewed 2023-12-14 · How we verify

NCT06170008

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of a Transparent Silicone Membrane With Physical Microstructure for Second-degree Burn Wounds and Skin Graft Wounds

Not yet recruiting NA Last updated 14 December 2023

What this trial tests

NA trial testing Physical microstructure-modified transparent silicone film sheet in Second-degree Burn Wounds in 40 participants. Not yet recruiting.

Timeline

30 December 2023

Primary endpoint
30 December 2026

30 December 2026

Quick facts

Lead sponsor	Changhai Hospital
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	30 December 2023
Primary completion	30 December 2026
Estimated completion	30 December 2026

Drugs / interventions tested

Physical microstructure-modified transparent silicone film sheet
Decellularized pig skin
Vaseline gauze

Conditions studied

Second-degree Burn Wounds — all drugs for Second-degree Burn Wounds →
Skin Graft Wounds — all drugs for Skin Graft Wounds →

Sponsor

Changhai Hospital

Who can join

Adults 12 to 70, any sex, with Second-degree Burn Wounds or Skin Graft Wounds. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to comparison of physical microstructure-modified transparent silicone films and current conventional trauma dressings for second-degree burn wounds and post-skin graft wounds.The main question it aims to answer is : The development of a new type of wound dressing is urgently needed because existing wound dressings cannot be transparent, easy to change, easy to store and inexpensive at the same time. Participants will receive routine wound treatment, after which they will be covered with a clear silicone membrane with physical microstructure modification. Researchers will compare vaseline gauze group and decellularised pigskin group o see if transparent silicone film with physical microstructure modifications promotes wound healing, reduces the number of dressing changes, reduces the damage to the wound and painful irritation to the patient during dressing changes, thus improving the quality of wound repair and saving medical costs.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Bioengineering of a human iPSC-derived vascularized endocrine pancreas for type 1 diabetes.
Campo F, Neroni A, Pignatelli C, Pellegrini S, et al · · 2025 · cited 3× · PMID 39922198 · DOI 10.1016/j.xcrm.2025.101938

Verify or expand the search:

Other Changhai Hospital trials

Trials by the same sponsor.

NCT07490002 — Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC · Phase 2 · not yet recruiting
NCT07464392 — FMT for the Prevention of Infectious Complications in Patients With Moderately Severe and Severe Acute Pancreatitis · NA · recruiting
NCT07507071 — Comparison of the Sensitivity of pCLE and Pathological Biopsy for Gastric Mucosal Lesions · not yet recruiting
NCT07481591 — Capsule Endoscopy in GI Bleeding: A Retrospective Study · not yet recruiting
NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06170008 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Changhai Hospital
Last refreshed: 14 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06170008.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing